smoking and glp 1 Join us on January 21 for an engaging discussion about the promise pitfalls of #GLP-1-based therapies, like #Ozempic, for cessation. We'll discuss potential therapeutic benefits, side effects and safety considerations GLP-1 and nicotine combination therapy
Description
In the PIONEER PLUS trial, for individuals with type 2 diabetes, a daily dose of 50 mg oral semaglutide achieved a weight loss of 9.8% over a continuous 68-week study period compared to 5.4% weight loss with a daily dose of 14 mg semaglutide
Randy Rudderman and his credentialed team offer effective solutions in a safe, patient-focused environment
FDA News Release
Ensure protein intake stays at target despite reduced hunger
Biomed Pharmacother 2023
